Flora Growth (NASDAQ:FLGC – Get Free Report) and Adagio Medical (NASDAQ:ADGM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Risk & Volatility
Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Adagio Medical has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500.
Earnings & Valuation
This table compares Flora Growth and Adagio Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Flora Growth | $57.61 million | 0.05 | -$15.91 million | ($32.49) | -0.09 |
| Adagio Medical | $600,000.00 | 4.39 | -$25.08 million | ($1.48) | -0.06 |
Flora Growth has higher revenue and earnings than Adagio Medical. Flora Growth is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Comparatively, 8.9% of Adagio Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations for Flora Growth and Adagio Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Flora Growth | 1 | 0 | 0 | 0 | 1.00 |
| Adagio Medical | 1 | 1 | 2 | 0 | 2.25 |
Adagio Medical has a consensus price target of $3.50, suggesting a potential upside of 3,542.04%. Given Adagio Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Adagio Medical is more favorable than Flora Growth.
Profitability
This table compares Flora Growth and Adagio Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Flora Growth | -32.03% | -64.02% | -34.46% |
| Adagio Medical | N/A | -661.85% | -73.35% |
Summary
Adagio Medical beats Flora Growth on 9 of the 14 factors compared between the two stocks.
About Flora Growth
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
About Adagio Medical
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.
Receive News & Ratings for Flora Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flora Growth and related companies with MarketBeat.com's FREE daily email newsletter.
